FDA Approved: KISUNLA — Supplemental Application (Eli Lilly and Company)

View source ↗

Summary

FDA approved a supplemental application for Kisunla (donanemab-azbt) from Eli Lilly and Company.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Kisunla (DONANEMAB-AZBT)

Snippet

SUPPL AP for KISUNLA (DONANEMAB-AZBT)